Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad ...

Voyager Therapeutics (VYGR) reported new data from its two preclinical programs targeting tau for the treatment of Alzheimer’s disease. Data on ...

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) have been given an average rating of “Buy” by the nine analysts that are covering the company, Marketbeat.com reports. Eight ...

Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical muri ...

(RTTNews) - Voyager Therapeutics, Inc. (VYGR), Monday, announced the presentation of new preclinical data at the AD/PD 2025 conference, showcasing its tau-targeting gene therapy VY1706 and anti ...

March 31, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported new data from ...

At close: March 28 at 4:00:01 PM EDT ...

The decision comes as the Voyager spacecraft face diminishing power supplies due to the gradual decay of their radioactive ...

The Lane 1 awards are part of the Space Force's launch plan that focuses on new or smaller companies that can grow into ...